Rampart touts new radiation safety consensus

A new multi-society consensus on occupational radiation safety backs enhanced radiation protection devices as a necessary step beyond lead apparel. Rampart says the guidance aligns with its lead-free platform, which it says is already in use in more than 250,000 procedures worldwide.

Why it matters: - The consensus signals a shift in how hospitals can protect clinicians during fluoroscopy-guided procedures. - The document ties radiation safety to two goals at once: lowering occupational exposure and reducing orthopedic strain from heavy lead apparel. - Rampart says the guidance supports broader adoption of lead-free enhanced radiation protection devices across interventional medicine.

What happened: - Rampart welcomed a multi-society expert consensus statement published by SCAI, ACC, ASE, HRS, SIR and SVS. - The statement calls for a fundamental shift in occupational radiation safety and describes enhanced radiation protection devices as a critical and mandatory evolution for healthcare professionals working in fluoroscopy-guided procedures. - The publication reframes ALARA, or As Low As Reasonably Achievable, around newer technology that can reduce both radiation exposure and physical burden. - Rampart said the company developed its Lead-Free ERPD™ platform before the consensus was published. - The company said the platform is designed to protect the entire procedural team with clinically validated lead-free materials.

The details: - Rampart says its Lead-Free ERPD™ platform has supported more than 250,000 procedures worldwide. - The platform is designed to deliver greater than 99% attenuation and 1mm lead-equivalent protection. - The system adds zero weight to clinicians or the patient table, according to Rampart. - The platform is built for coronary, electrophysiology, endovascular, neuro and aortic procedures. - Dr. David Rizik, an interventional cardiologist and service line executive at Banner Health, said Arizona’s first lead-apron-free procedures using the Rampart System took place earlier this year. - The consensus also urges fluoroscopy manufacturers to advance radiation protection through equipment design. - Rampart says it is already working with global imaging manufacturers on next-generation interventional suites. - Those collaborations focus on preserving physician access, maintaining imaging performance without increasing patient radiation risk, and supporting efficient workflows. - Rampart says its vertically integrated manufacturing model supports a 30-day delivery commitment and same-day installation. - The company says it is the sole worldwide manufacturer of lead-free bismuth acrylic and produces its ClearShield® Technology in-house. - Rampart says dedicated installation engineers, project managers and an in-house medical physicist support implementation. - Tom Livingston, chief executive officer of Rampart, said the company is focused on dependable supply and scalable implementation as well as innovation. - Dr. Bob Foster, Rampart’s chief medical officer, said clinicians should not have to choose between radiation protection and orthopedic injury.

Between the lines: - The consensus gives hospitals and device makers a shared clinical signal that the next phase of radiation safety may favor built-in protection over wearable lead. - Rampart is positioning itself as both a technology provider and an implementation partner, which could matter as hospitals look for lower-friction ways to adopt new workflows. - The company is also using evidence from randomized trials and real-world procedures to support its claim that lead-free protection is ready for broader use.

What's next: - Rampart said it will keep working with imaging manufacturers to bring enhanced radiation protection into new interventional suite designs. - Hospitals interested in the platform can find more information in Rampart’s announcement. - The broader market will now watch whether the multi-society consensus accelerates adoption of ERPDs across cath labs and other fluoroscopy-heavy settings.

The bottom line: - The consensus elevates lead-free radiation protection from a promising option to a clinical direction hospitals are now being asked to consider.